Clinical Trials Directory
This study lasts about six months. Before starting, participants will have health checks, including a physical exam, blood tests, and other assessments. Some participants may also have a pregnancy test. Participants will be placed into one of two groups by chance. One group will receive a treatment called remestemcel along with a medicine called ruxolitinib. The other group will receive a placebo, which has no active medicine, along with ruxolitinib. Neither the participants nor the study doctors will know which group each person is in. Remestemcel or the placebo is given through a vein twice a week for four weeks. Some people may receive extra weekly doses depending on how well they respond. Ruxolitinib is taken by mouth twice a day for up to 56 days. During the study, participants will have regular visits, blood tests, health checks, and quality of life questionnaires. The goal is to learn if this treatment can help people with severe graft versus host disease after a blood or bone marrow transplant.
This study is not testing a new treatment. People will continue to receive their usual medical care, such as a stem cell transplant or gene therapy. If they join the study, they will give blood samples during their regular visits over about five years. They may also choose to give other samples, such as stool, skin, hair, nails, or bone marrow. These samples will help researchers learn more about how the body responds to these treatments over time.
We are doing this study to try and find a way to detect breast cancer earlier or before it recurs.
This study has three parts: 1. Screening Period (about 10 days): You will go to the clinic for tests like a brain scan (MRI), blood tests, heart check (EKG), and physical and brain exams. 2. Study Dosing Period: You will get a medicine called BRiTE through a small tube in your vein using a portable pump. It will run for 4 days. Then, you will not get any medicine for 24 days. This is called one cycle. You will go through 3 cycles like this. 3. Follow-Up Period: Doctors will keep checking on you with exams, blood tests, heart checks, and brain scans. You will visit the clinic every 8 weeks to make sure everything is going well.
In this study, people will take a medicine called R289 by mouth once or twice a day. The study has two parts: one part is to find the best dose, and the other part is to test two different doses. You may take the medicine at home or at the clinic. You will visit the clinic regularly for tests like blood work, physical check-ups, and heart exams. Some visits may take up to 8 hours. You can stay in the study as long as the medicine is helping and the side effects are not too strong.
This study does not test a new treatment. People will continue to receive their regular transplant care. The study looks at blood and DNA samples to learn if a blood test called AlloHeme can help doctors find signs that a disease may come back after a transplant. For donors, the study lasts about two years. They will give a blood sample before the transplant and then provide blood samples and a cheek swab during follow up visits after the transplant. Researchers will compare the donor and recipient DNA samples to look for early signs that the disease might return. For transplant recipients, participation is much shorter. They will provide one small blood sample for DNA testing during a single study visit that lasts about 30 minutes. After that sample is collected, their participation in the study is complete.
We are doing this study to find out if an experimental drug called CAP-100 (study drug) is a safe and effective treatment for people who have CLL or SLL that is not responding to standard treatments. We also want to know what dose of this study drug works best.
We are doing this study to monitor the health and quality of life of people who participated in clinical trials for GM T cell therapies.